COMP <GO>
ALGS vs ESLA // EV/EBITDA & P/E VALUATION
Aligos Therapeutics Inc. (NASDAQ) VS. Estrella Immunopharma Inc. (NASDAQ) • 15-METRIC TALLY: ALGS 1
— ESLA 2
■ METRIC PARITY
LAST: $5.03 (-2.71%) • MKT CAP: $31.4M
valuation
—
LAST: $0.73 (-11.32%) • MKT CAP: $31.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALGS VS. ESLA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALGS | ESLA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -5.63% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -39.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | ALGS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 51.5 | -10.40 | ESLA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.4M | $31.7M | -$286.8K | ESLA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALGS REV | ESLA REV | ALGS GROSS % | ESLA GROSS % | ALGS FCF | ESLA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.2M | $0 | — | — | -$82.5M | -$1.8M |
| FY 2024 | $3.6M | $0 | — | — | -$80.9M | -$16.1M |
| FY 2023 | $6.2M | $0 | — | — | -$79.0M | -$1.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALGS // BETA —
ESLA // BETA —